Royal Bank of Canada Has $112.05 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Royal Bank of Canada boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 834,041 shares of the medical research company's stock after buying an additional 39,321 shares during the period. Royal Bank of Canada owned approximately 0.29% of Agilent Technologies worth $112,045,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CKW Financial Group grew its stake in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Global X Japan Co. Ltd. boosted its stake in shares of Agilent Technologies by 161.1% during the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock worth $25,000 after acquiring an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new stake in shares of Agilent Technologies during the 4th quarter worth about $27,000. Lee Danner & Bass Inc. bought a new stake in shares of Agilent Technologies during the 4th quarter worth about $29,000. Finally, Hanson & Doremus Investment Management boosted its stake in shares of Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 87.42% of the company's stock.

Insider Transactions at Agilent Technologies

In related news, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares of the company's stock, valued at $2,657,456.28. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company's stock, valued at $4,161,931.02. This represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.26% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A has been the subject of several recent analyst reports. TD Cowen upped their price target on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Robert W. Baird decreased their price target on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Wells Fargo & Company decreased their price target on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Jefferies Financial Group decreased their price target on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research note on Monday, April 21st. Finally, Barclays decreased their price target on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $143.00.

Agilent Technologies Price Performance

Shares of A stock opened at $113.32 on Tuesday. The stock has a 50 day moving average of $110.31 and a two-hundred day moving average of $127.99. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $154.95. The company has a market capitalization of $32.31 billion, a P/E ratio of 26.05, a P/E/G ratio of 3.21 and a beta of 1.27.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st were issued a $0.248 dividend. The ex-dividend date was Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.88%. Agilent Technologies's payout ratio is presently 22.76%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.